Canarypox Virus

Overview and Taxonomy of Canarypox Virus

Taxonomic Classification and Phylogenetic Position

Canarypox virus (CNPV) is a member of the genus Avipoxvirus within the subfamily Chordopoxvirinae of the family Poxviridae. This family encompasses a diverse array of large, double-stranded DNA viruses that replicate exclusively within the cytoplasm of infected cells. The genus Avipoxvirus is distinguished by its host range, which is largely restricted to avian species, and by its unique biological and genomic characteristics. Within this genus, CNPV is classified alongside other well-characterized members such as fowlpox virus (FWPV), pigeonpox virus, and turkeypox virus. The taxonomic delineation of avipoxviruses has historically been based on host species and the nature of clinical lesions, but modern molecular phylogenetic analyses have refined these classifications, revealing a more complex evolutionary landscape.

Phylogenetic studies, particularly those targeting the core P4b protein gene (also known as the fpv167 locus), have been instrumental in resolving the relationships among avipoxviruses. These analyses have consistently demonstrated that CNPV isolates form a distinct clade, often referred to as the "canarypox-like viruses," which is separate from the "fowlpox-like viruses" that primarily infect Galliformes [15]. This genetic divergence is not merely a taxonomic curiosity; it has profound implications for host range, pathogenicity, and the evolution of virulence factors. The B1 subclade of CNPV, in particular, has garnered significant attention due to its association with severe, systemic disease in passerine species. As documented by Sinnott et al. (2023), sequencing of the core P4b protein gene from systemic avian poxvirus cases in a zoological collection grouped all isolates into cluster 2 of the B1 subclade [1]. This finding underscores the pathogenic potential of specific viral lineages and suggests that systemic spread, a rare and often fatal manifestation of avian pox, may be linked to particular strain variations within the B1 subclade [1]. The ability to differentiate these subclades is critical for epidemiological surveillance and for understanding the molecular determinants of virulence.

Genomic Architecture and Biological Characteristics

The CNPV genome is a linear, double-stranded DNA molecule approximately 300–380 kilobase pairs (kbp) in length, making it one of the largest among the poxviruses. The genome is characterized by a central conserved core region that encodes essential genes for viral replication, transcription, and assembly, flanked by variable terminal regions that contain genes involved in host range, immune evasion, and pathogenesis. The complete genome sequencing of different avipoxviruses, including CNPV, is essential for unraveling the complex paradigm of host range and for understanding the molecular epidemiology of these viruses [15]. The genomic plasticity of CNPV, particularly in the terminal regions, allows for the acquisition and loss of genes that modulate host interactions, a feature that has been exploited for the development of recombinant vaccine vectors.

One of the most striking biological characteristics of CNPV is its ability to undergo a productive, lytic infection in avian cells but a non-productive, abortive infection in mammalian cells. This host restriction is a defining feature of the genus Avipoxvirus and is the foundation for the safety of CNPV-based recombinant vaccines in mammals. In mammalian cells, the virus enters and initiates early gene expression but fails to complete the replication cycle, preventing the production of infectious progeny. Despite this abortive infection, the viral antigens are expressed and processed, leading to the induction of robust humoral and cellular immune responses. This unique property has made CNPV, particularly the ALVAC strain (a highly attenuated derivative), an exceptionally safe and effective vector platform for vaccine development against a wide range of pathogens in both veterinary and human medicine.

Host Range and Epidemiology

The host range of CNPV is primarily restricted to passerine birds (order Passeriformes), which includes canaries, finches, sparrows, and related species. However, the host specificity of avipoxviruses is now understood to be broader than previously thought. While "fowlpox-like viruses" are mainly isolated from Galliformes and "canarypox-like viruses" from Passeriformes, viruses have also been documented in Psittaciformes (parrots and related species) [15]. This expanded host range highlights the potential for cross-species transmission and the emergence of novel viral variants, which poses a significant challenge for disease control in both wild and captive bird populations.

Epidemiologically, CNPV is a significant pathogen in canary breeding operations and aviaries worldwide. Outbreaks can result in substantial morbidity and mortality, as exemplified by a severe epizootic in Lebanon that led to approximately 50% mortality in affected canary flocks [6]. The virus is transmitted mechanically by arthropod vectors, such as mosquitoes and mites, as well as through direct contact with infected birds or contaminated fomites. The incubation period typically ranges from 4 to 10 days, after which clinical signs develop. The disease manifests in two classical forms: cutaneous ("dry") pox, characterized by proliferative, wart-like nodules on the unfeathered skin of the eyelids, beak, legs, and feet; and diphtheritic ("wet") pox, characterized by caseous plaques and diphtheritic membranes in the oropharynx, upper respiratory tract, and gastrointestinal tract [1]. The diphtheritic form is often more severe and is associated with higher mortality due to respiratory obstruction and secondary bacterial infections.

Pathogenesis and Systemic Spread

The pathogenesis of CNPV infection begins with viral entry through abrasions or breaks in the skin or mucous membranes. The virus replicates locally in epithelial cells, leading to cellular hyperplasia and hypertrophy, which results in the characteristic proliferative lesions. Histopathologically, these lesions are marked by ballooning degeneration of epithelial cells and the presence of large, intracytoplasmic inclusion bodies known as Bollinger bodies, which are aggregates of mature virions [6]. These inclusions are a pathognomonic feature of avipoxvirus infections and are readily identifiable on routine hematoxylin and eosin staining.

While the majority of CNPV infections remain localized to the skin and mucous membranes, systemic spread to visceral organs is a rare but well-documented phenomenon. A comprehensive retrospective study spanning 20 years at a zoological institution identified 22 cases of systemic avian poxvirus out of 151 total diagnoses, with all systemic cases attributed to the B1 subclade of CNPV [1]. Grossly, systemic involvement is characterized by soft, white nodules scattered throughout the liver, spleen, and kidneys. Histopathologically, two distinct patterns emerge: (1) widespread histiocytic inflammation in visceral organs with intrahistiocytic viral inclusions, and (2) severe, localized dry or wet pox lesions with poxvirus-like inclusions within dermal and subepithelial histiocytes [1]. The use of in situ hybridization targeting the core P4b protein gene has confirmed the presence of viral DNA within histiocytes in both patterns, indicating that these cells are a primary target for viral dissemination [1]. The mechanisms underlying systemic spread are not fully understood but are likely a complex interplay between specific viral strain variations (particularly within the B1 subclade), host immune status, and environmental stressors [1]. The identification of identical reticuloendotheliosis virus (REV) long terminal repeat (LTR) flanking region sequences in systemic pox cases and a condorpox virus isolate from an Andean condor suggests that recombination events or shared genetic elements may contribute to the enhanced virulence and systemic dissemination observed in these cases [1].

The ALVAC Strain: A Paradigm for Vaccine Vector Development

The ALVAC strain of CNPV is a highly attenuated, tissue culture-adapted derivative that was developed specifically for use as a recombinant vaccine vector. Its safety profile is exemplary, stemming from its inability to replicate productively in mammalian cells. This abortive infection, however, is sufficient to drive potent immune responses, making ALVAC an ideal platform for delivering heterologous antigens. The World Organisation for Animal Health (WOAH) and the World Health Organization (WHO) have recognized the importance of such non-replicating vectors for the development of safe and effective vaccines, particularly for zoonotic diseases.

The utility of ALVAC has been demonstrated across a remarkable breadth of veterinary applications. In companion animals, ALVAC-vectored vaccines have been developed for canine distemper virus (CDV), feline leukemia virus (FeLV), and rabies virus. For CDV, a recombinant ALVAC expressing the hemagglutinin (H) and fusion (F) glycoproteins of CDV has been shown to be safe and highly efficacious, protecting specific-pathogen-free Beagle pups against a virulent challenge with 0% morbidity and mortality compared to 100% morbidity and 86% mortality in controls [11]. More recent advances using CRISPR/Cas9 gene editing technology have enabled the construction of a highly efficient recombinant ALVAC-CDV-M-F-H/C5- strain that co-expresses the matrix (M), H, and F proteins, leading to faster seroconversion and higher antibody positivity rates in foxes and minks [3]. This demonstrates the power of modern molecular tools to enhance the immunogenicity of ALVAC-based vaccines.

In feline medicine, ALVAC-vectored vaccines have been developed for FeLV and rabies. The concurrent administration of Purevax FeLV and Purevax Rabies (both ALVAC-vectored) has been shown to be safe and non-interfering, with no significant difference in anti-rabies antibody titers between cats receiving concurrent versus separate vaccinations [2]. This is a critical practical consideration, as it reduces the number of veterinary visits and associated stress for both cats and owners. However, it is important to note that the efficacy of ALVAC-vectored FeLV vaccines has been a subject of debate. Comparative studies have shown that an inactivated, adjuvanted whole-virus FeLV vaccine (Nobivac feline 2-FeLV) provided significantly better protection against persistent antigenemia and had significantly lower proviral DNA and viral RNA loads compared to the ALVAC-vectored PureVax recombinant FeLV vaccine [9]. Similarly, a novel non-adjuvanted replicon RNA particle (RP) vaccine expressing the FeLV envelope protein demonstrated superior protection compared to the canarypox-vectored FeLV vaccine, with 0% of RP-vaccinated cats developing persistent antigenemia versus 30-43% of canarypox-vectored vaccine recipients [13]. These findings highlight that while ALVAC is a versatile and safe vector, the immunogenicity of the expressed antigen and the specific vaccine formulation are critical determinants of protective efficacy.

In equine medicine, ALVAC-vectored vaccines have been developed for equine influenza virus (EIV) and Hendra virus (HeV). The recombinant canarypox-vectored EIV vaccine (ProteqFlu) encodes the hemagglutinin (HA) of two EIV strains and has been shown to induce cross-reactive antibody responses and clinical protection, even when the vaccine strains are antigenically distinct from the circulating field virus [8]. Concurrent vaccination with the ALVAC-vectored EIV vaccine and an inactivated equine herpesvirus (EHV) vaccine has been shown to significantly enhance EIV-specific IFN-γ production without compromising humoral responses, suggesting a beneficial adjuvant effect [7]. Furthermore, the addition of adjuvants such as monophosphoryl lipid A (MPL) and polyinosinic-polycytidylic acid (poly I:C) to the ALVAC-vectored EIV vaccine significantly enhanced serum IgG antibody concentrations, hemagglutination inhibition titers, and memory B cell responses, demonstrating that the immune response to ALVAC vectors can be further potentiated [14].

For Hendra virus, a highly lethal zoonotic paramyxovirus, an ALVAC-vectored vaccine expressing the HeV attachment glycoprotein (G) and fusion protein (F) has been developed. In hamsters, the vaccine efficiently prevented oropharyngeal virus shedding and protected animals from clinical disease and virus-induced mortality [10]. Notably, some vaccinated animals were protected even in the absence of detectable specific antibodies, suggesting the induction of an efficient virus-specific cellular immunity [10]. Immunized ponies developed strong seroneutralizing titers against both HeV and the closely related Nipah virus, indicating the potential for cross-protection against henipavirus infection [10]. This vaccine represents a critical tool for protecting horses and, by extension, humans who are exposed to sick horses, aligning with the WOAH and FAO One Health approach to zoonotic disease control.

Innate Immune Activation and Molecular Mechanisms

The immunogenicity of ALVAC is not merely a passive consequence of antigen expression; it is actively driven by the vector's ability to stimulate the innate immune system. ALVAC acts as a potent adjuvant through a mechanism that involves the activation of natural killer (NK) cells and dendritic cells (DCs). Studies have demonstrated that ALVAC triggers the release of interferon-gamma (IFN-γ) by NK cells, which is essential for Th1 polarization and the augmentation of antigen-specific IgG2a responses [12]. Immuno-depletion of NK cells prior to ALVAC immunization abrogates IFN-γ production, confirming that NK cells are the main cellular source of early IFN-γ in vivo [12]. Furthermore, murine bone marrow-derived dendritic cells (BMDCs) cultured in the presence of ALVAC secrete high levels of the chemokines CXCL10 and CCL2 and up-regulate the expression of maturation markers CD40, CD80, and CD86 [12].

At the molecular level, ALVAC engages the cGAS/IFI16-STING-type I IFN pathway to prime the AIM2 inflammasome, leading to robust inflammasome activation in both human and mouse antigen-presenting cells [4]. This pathway is functionally required for ALVAC-induced inflammasome activation, and the AIM2 sensor is identified as a key innate sensor for ALVAC [4]. This contrasts with adenovirus vectors, which are unable to induce inflammasome activation due to their inability to stimulate the STING-type I IFN pathway [4]. The ability of ALVAC to trigger this specific innate signaling cascade is a unique feature that contributes to its potent immunogenicity and its ability to induce strong Th1-biased immune responses. Additionally, CNPV encodes a Bcl-2-like protein, CNP058, which acts as a potent inhibitor of apoptosis by binding to a broad range of host pro-death Bcl-2 proteins, including Bak, Bax, and several BH3-only proteins [5]. This anti-apoptotic function likely plays a key role in countering premature host cell death during viral replication in avian cells, thereby facilitating efficient viral progeny production [5].

Molecular Pathogenesis of Canarypox Virus: Mechanisms of Systemic Infection

Canarypox virus (CNPV), a member of the genus Avipoxvirus within the family Poxviridae, has long been recognized as a pathogen primarily causing localized cutaneous (“dry”) and diphtheritic (“wet”) pox lesions in passeriform birds, especially canaries (Serinus canaria domesticus). However, accumulating evidence over the past two decades has unveiled a far more sinister pathogenic potential: the capacity for systemic dissemination to visceral organs, leading to fulminant multiorgan failure and high mortality. Understanding the molecular underpinnings of this systemic infection requires an integrated analysis of viral strain specificity, host innate immune evasion, intracellular signaling subversion, and the interplay between viral anti-apoptotic machinery and inflammasome activation. This section dissects these mechanisms in exhaustive detail, drawing primarily from the landmark 2023 study by Sinnott et al. [1] that systematically characterized systemic avian poxvirus infections in a zoological collection, alongside complementary molecular studies on CNPV-encoded proteins and host-pathogen interactions.

Strain-Specific Determinants of Systemic Dissemination: The B1 Subclade Paradigm

The foundation of systemic pathogenesis lies in the genetic identity of the infecting virus. Sinnott et al. [1] performed a 20-year retrospective analysis of 151 avian poxvirus cases, identifying 22 with systemic involvement based on histopathology and PCR. Crucially, sequencing of the core P4b protein gene, a highly conserved region used for avipoxvirus phylogeny, revealed that all systemic cases clustered into cluster 2 of the B1 subclade of canarypox viruses [1]. This finding is not merely taxonomic; it suggests that specific amino acid residues within the P4b gene product, or linked genomic loci, confer the ability to evade local immune containment and hematogenously or lymphatically spread to the liver, spleen, and kidneys. The B1 subclade is distinct from the more commonly encountered A and C clades that typically cause self-limiting cutaneous lesions. Furthermore, analysis of the reticuloendotheliosis virus (REV) long terminal repeat (LTR) flanking region yielded sequences identical to a condorpox virus isolate previously associated with systemic pox in an Andean condor [1]. This identity implies horizontal transfer or ancient recombination events involving retroviral elements that may modulate viral virulence. The REV LTR region is known to contain enhancer and promoter elements capable of influencing adjacent poxviral gene expression; its presence in systemic strains could upregulate genes involved in immune evasion or cellular tropism expansion. Thus, systemic canarypox infection appears to be a B1 subclade-driven phenomenon, likely potentiated by ancillary genetic elements such as integrated retroviral sequences.

Cellular Tropism and Histiocyte-Mediated Dissemination

The histopathological hallmark of systemic CNPV infection, as documented by Sinnott et al. [1], is the presence of two distinct patterns: (1) widespread histiocytic inflammation in visceral organs with intrahistiocytic viral inclusions, and (2) severe localized dry or wet pox lesions with poxvirus-like inclusions within dermal and subepithelial histiocytes. In situ hybridization targeting the P4b gene confirmed poxvirus DNA within these histiocytes in both patterns [1]. This observation is pivotal: histiocytes, tissue-resident macrophages and dendritic cells, serve as both viral reservoirs and vehicles for dissemination. Unlike epithelial cells, which are the primary targets in cutaneous pox, histiocytes are motile and capable of trafficking through lymphatic and blood vessels. The virus must therefore possess molecular mechanisms to enter, replicate within, and exit these phagocytic cells without triggering rapid cytolysis. Poxviruses encode a suite of immunomodulatory proteins; in CNPV, the Bcl-2 mimic CNP058 (discussed below) likely inhibits apoptosis in infected histiocytes, prolonging their survival and facilitating systemic spread [5]. Moreover, the ability of CNPV to infect macrophages is consistent with the known tropism of the closely related fowlpox virus, which also infects mononuclear cells [15]. The shift from epithelial to histiocytic tropism in systemic strains may be mediated by alterations in the viral entry machinery, such as changes in the envelope proteins that bind host cell receptors, although direct evidence for CNPV remains limited.

Subversion of Apoptosis: CNP058 as a Master Regulator

Programmed cell death represents a critical host defense against viral propagation, and CNPV has evolved a potent countermeasure: the Bcl-2-like protein CNP058. Structural and functional studies by Anasir et al. [5] demonstrated that CNP058 adopts the canonical Bcl-2 fold and binds a broad spectrum of pro-apoptotic Bcl-2 family members, including Bak, Bax, and multiple BH3-only proteins (Bim, Bid, Bmf, Noxa, Puma, and Hrk) with high to moderate affinities. This promiscuous binding is unusual, cellular pro-survival Bcl-2 proteins typically exhibit narrower specificity. CNP058 was shown to potently inhibit ultraviolet-induced apoptosis in cell culture [5]. In the context of systemic infection, this anti-apoptotic activity is likely indispensable for two reasons: first, it prevents premature death of infected histiocytes, allowing the virus to complete its replication cycle and produce progeny virions; second, it counters the extrinsic apoptosis pathway triggered by cytotoxic T lymphocytes and natural killer cells. The B1 subclade strains associated with systemic disease may express CNP058 at higher levels or with enhanced binding affinity, although comparative studies are lacking. Given that other poxviruses, such as fowlpox virus (FWPV), also encode Bcl-2 homologs [15], CNP058 represents a conserved but uniquely adapted virulence factor in CNPV.

Inflammasome Priming and the cGAS/IFI16-STING-AIM2 Axis

While CNPV actively inhibits apoptosis, it simultaneously triggers powerful innate immune responses. Liu et al. [4] elucidated a critical pathway: the canarypox vector ALVAC (a live attenuated CNPV strain) activates the AIM2 inflammasome in human and mouse antigen-presenting cells (APCs). This activation depends on a two-step process. First, ALVAC stimulates the cGAS/IFI16–STING–type I IFN pathway, which provides the priming signal necessary for AIM2 expression. Second, cytosolic DNA from the viral genome, likely released during uncoating or replication, directly engages AIM2, leading to inflammasome assembly and IL-1β/IL-18 secretion [4]. Notably, this pathway was identified using ALVAC, which is a laboratory-attenuated strain; wild-type CNPV, particularly B1 subclade isolates, may elicit an even more robust response. The significance of inflammasome activation in systemic infection is twofold. IL-18 is a potent inducer of IFN-γ from NK cells and T cells, and IFN-γ is crucial for Th1 polarization and antiviral immunity [12]. However, excessive inflammasome activation can contribute to immunopathology, including the histiocytic inflammation and tissue necrosis observed in systemic cases [1]. Moreover, the STING pathway also drives type I IFN production, which can upregulate MHC class I and antiviral genes. The balance between beneficial antiviral effects and detrimental inflammation likely determines the outcome, localized versus systemic disease. Intriguingly, the B1 subclade strains may have evolved mechanisms to dampen STING signaling or to delay AIM2 activation, allowing early replication in histiocytes before the immune response becomes fully established.

Natural Killer Cell Engagement and Th1 Polarization

The innate immune response to CNPV is not limited to APCs. Ryan et al. [12] demonstrated that ALVAC immunization in mice leads to rapid IFN-γ production by natural killer (NK) cells, which is required for subsequent Th1 polarization of adaptive immunity. Immunodepletion of NK cells abrogated IFN-γ, and bone marrow-derived dendritic cells exposed to ALVAC secreted CXCL10 and CCL2 and upregulate costimulatory molecules [12]. In systemic CNPV infection, NK cells infiltrating visceral organs, such as the liver and spleen, likely contribute to early viral control. However, the same IFN-γ-driven inflammation may exacerbate tissue damage when viral replication is unchecked. The B1 subclade's ability to infect histiocytes could also undermine NK cell function by altering the cytokine milieu at the site of infection. Additionally, the concurrent expression of viral interleukin-2 (IL-2) homologs or other immunomodulators, not explicitly studied in wild-type CNPV but known from recombinant constructs [16], might further skew the immune response. The use of ALVAC expressing feline IL-2 as an adjuvant immunotherapy for feline injection-site sarcomas [16] illustrates the capacity of CNPV vectors to influence cytokine networks. In a natural systemic infection, such cytokine manipulation could be either beneficial (limiting spread) or deleterious (promoting histiocyte recruitment and viral dissemination).

Hematogenous and Lymphatic Dissemination: From Skin to Viscera

The transition from a localized epithelial infection to systemic involvement requires breaching of the vascular or lymphatic barriers. Histopathological evidence from [1] shows viral inclusions in histiocytes within the dermis and subepithelial layers, which are richly supplied with lymphatics. Infected histiocytes can migrate to regional lymph nodes and subsequently enter the bloodstream via the thoracic duct. Once in the circulation, the virus can seed the liver (Kupffer cells), spleen (splenic macrophages), and kidneys (interstitial macrophages). The observation of soft white nodules in these organs [1] is consistent with foci of histiocytic proliferation and viral replication. The liver, in particular, is a major target because of its extensive reticuloendothelial network. The virus must also resist complement-mediated lysis and neutralization by pre-existing antibodies, a feat aided by poxviral complement control proteins (e.g., homologs of vaccinia virus VCP). While not explicitly demonstrated for CNPV, such proteins are encoded in the genomes of related avipoxviruses [15]. The B1 subclade may possess enhanced complement evasion capabilities, further enabling systemic spread.

Host Factors and Environmental Modulation

Systemic infection is not an inevitable consequence of B1 subclade exposure. Sinnott et al. [1] emphasized that systemic involvement likely results from a combination of viral strain variation, host immune status, and environmental cofactors. In their study, the affected birds were from a zoological collection, suggesting that stress, concurrent infections (e.g., Mycoplasma gallisepticum as identified in a Lebanese canarypox outbreak [6]), or immunosuppression may predispose to dissemination. The canary outbreak described by Shaib and Barbour [6] resulted in 50% mortality with rapid death (5–6 days) and histopathological evidence of airsacculitis, but not the classic histiocytic pattern, possibly because it was a different CNPV lineage (100% sequence identity to an Iranian isolate, not necessarily B1 subclade). This underscores the importance of strain-specific pathogenicity. Molecularly, host factors such as polymorphisms in STING, AIM2, or IFN-γ receptor genes could influence susceptibility. Unfortunately, avian immunogenetics remain poorly characterized. From a practical standpoint, the World Organisation for Animal Health (WOAH) recognizes avian pox as a notifiable disease in some contexts, and the emergence of systemic strains poses challenges for vaccination strategies. The development of recombinant CNPV vaccines (e.g., for canine distemper [3], rabies [17], or Hendra virus [10]) has relied on ALVAC’s safety profile, but live attenuated strains could theoretically revert to virulence or recombine with field strains. Understanding the molecular determinants of systemic pathogenesis, particularly the role of the B1 subclade P4b gene and associated REV LTR elements, is crucial for designing next-generation vaccines that are both immunogenic and incapable of systemic spread.

In summary, the molecular pathogenesis of systemic canarypox infection is a multi-faceted process involving strain-specific genetic determinants (B1 subclade, REV LTR), cellular tropism for histiocytes, potent anti-apoptotic machinery (CNP058), inflammasome priming through the cGAS/IFI16-STING-AIM2 axis, NK cell-derived IFN-γ, and hematogenous dissemination. Each of these steps represents a potential target for therapeutic intervention or vaccine design, though much remains to be elucidated at the level of individual viral gene functions and host receptor interactions.

Epidemiology of Canarypox Virus: Host Range, Transmission, and Risk Factors

The epidemiology of canarypox virus (CNPV) is a complex interplay of viral genetic diversity, host species susceptibility, ecological vectors, and management practices, rendering it a disease of significant concern for aviculture, conservation, and the broader poultry industry. Unlike its more extensively studied relative, fowlpox virus (FWPV), CNPV presents a distinct host range predicated on evolutionary adaptations that shape its transmission dynamics and pathogenic potential. Understanding these epidemiological parameters is not merely an academic exercise; it is fundamentally crucial for designing effective surveillance, biosecurity, and vaccination strategies, particularly in the context of threatened and endangered passerine populations and the growing use of CNPV as a vaccine vector platform.

Host Range: A Spectrum of Susceptibility

The host range of avipoxviruses is a defining characteristic of their ecology, traditionally classified into three broad groups: (1) ‘fowlpox-like viruses’ primarily infecting Galliformes, (2) ‘canarypox-like viruses’ predominantly affecting Passeriformes, and (3) viruses associated with Psittaciformes [15]. This host restriction, while not absolute, provides the foundational framework for understanding CNPV epidemiology. The virus is most notoriously pathogenic for species within the order Passeriformes, with canaries (Serinus canaria domesticus) serving as the classical and most severely affected host. A documented outbreak among domestic canaries in Lebanon, where approximately 50% of birds on multiple breeding farms succumbed, starkly illustrates the devastating potential of CNPV within susceptible passerine populations [6]. Infected birds presented with characteristic lesions, thickened eyelids, scab-like lesions on the beak, foot, and caudal regions, with death occurring a mere 5–6 days post-symptom onset [6]. This rapid disease course and high mortality underscore the acute virulence of field strains for their native hosts.

However, the host range extends well beyond canaries. Evidence from a comprehensive 20-year retrospective study at a zoological institution revealed that systemic avian poxvirus infections, which are rarely reported in the literature, occurred in 22 out of 151 diagnosed cases [1]. Critically, molecular characterization of these systemic cases demonstrated that the causative poxvirus sequences grouped into cluster 2 of the B1 subclade of CNPV [1]. This finding is epidemiologically profound, as it indicates that CNPV strains, or closely related variants, are capable of causing severe, disseminated disease in a wide array of non-passerine species housed in captivity, including a condor (a New World vulture). The virus was capable of infecting and replicating within histiocytes in visceral organs such as the liver, spleen, and kidneys, leading to grossly visible white nodules and a systemic histiocytic inflammatory pattern [1]. This suggests that under certain conditions, the host range of CNPV is broader than historically assumed, particularly in zoological settings where novel host-virus encounters can occur.

Adding further complexity, the host range of CNPV is not limited to causing disease. The virus has been extensively exploited as a vector for recombinant vaccine development across a variety of mammalian species, including cats, dogs, horses, ferrets, and even non-human primates [2-5, 7-12, 14, 17-20]. In these hosts, the canarypox virus (most commonly the attenuated ALVAC strain) is replication-competent in avian cells but undergoes an abortive replication cycle in mammalian cells. This non-productive infection is a safety feature that still allows for robust transgene expression and potent immunogenicity without causing poxviral disease. For instance, CNPV-vectored vaccines have proven effective against feline leukemia virus (FeLV), rabies virus, canine distemper virus (CDV), and equine influenza virus (EIV) [2, 3, 7-9, 11, 13, 17]. The very fact that CNPV can enter, express genes in, and stimulate the innate immune system of such a diverse array of mammalian species, activating AIM2 inflammasomes and cGAS/IFI16-STING pathways in human and mouse antigen-presenting cells, and triggering IFN-γ production from natural killer (NK) cells [4, 12], highlights a broad cellular tropism at the level of entry and early gene expression, even though disease is restricted to its natural avian hosts. Thus, the true host range of CNPV must be delineated into two categories: the susceptible host range (where the virus completes its replication cycle and causes disease, primarily passerines) and the permissive host range (where the virus can infect cells and express genes but does not cause clinical disease, encompassing many mammals).

Transmission Dynamics: Vectors, Direct Contact, and Fomites

The primary mode of transmission for CNPV, as for all avipoxviruses, is mechanical transmission via arthropod vectors, predominantly mosquitoes and other blood-feeding flies [15]. This vector-borne nature dictates the seasonal and geographic patterns of the disease. Outbreaks are more frequent in warm, humid climates and during periods of vector abundance [6, 15]. The virus does not replicate within the vector; instead, it is carried on the mouthparts and proboscis of the arthropod, which introduces the virus into the skin of a susceptible bird during a blood meal. The resulting infection typically manifests as the cutaneous or “dry” form, characterized by proliferative nodules on unfeathered areas such as the face, legs, and feet. The ability of CNPV to be vectored by multiple insect species contributes to its persistence in the environment and its potential for rapid spread within a naïve population.

While less efficient, direct transmission can also occur through contact with infected birds or contaminated fomites. Virus-laden scabs and exudate from cutaneous lesions are highly infectious and can be shed into the environment, contaminating perches, feed, water, and cages. Inhalation or ingestion of these desquamated scabs can lead to the diphtheritic or “wet” form, where lesions form on the mucous membranes of the oropharynx, upper respiratory tract, and gastrointestinal tract [1, 15]. This form is particularly severe, as it can impede feeding and respiration, and is more frequently associated with systemic spread [1]. The Lebanese outbreak, for instance, was exacerbated by poor biosecurity and the smuggling of pet birds, highlighting how human activity, trade and movement, can bypass natural vector-driven transmission and introduce the virus into new, vulnerable populations [6]. Once introduced, conditions of high bird density, stress, and poor sanitation on breeding farms create an amplification cycle, facilitating rapid direct and fomite transmission among birds.

Risk Factors: Genetic, Host, and Environmental Determinants

The outcome of CNPV exposure is not uniform; it is heavily modulated by a constellation of risk factors that determine whether an infection will remain localized, become systemic, or result in mortality.

1. Viral Genetic Factors: Perhaps the most significant risk factor for severe disease is the specific strain of CNPV. The B1 subclade of CNPV, particularly cluster 2, has been molecularly linked to a markedly increased risk of systemic infection [1]. In the zoo-based study, all 22 cases of systemic pox were caused by viruses within this subclade, and the sequences of the reticuloendothelial virus (REV) long terminal repeat (LTR) flanking region from these systemic cases were identical to a previously described condorpox virus isolate [1]. This suggests that the genetic architecture of the virus, specifically elements flanking the REV LTR and the core P4b protein gene, harbors determinants that govern the capacity for visceral dissemination. Such strains are likely more adept at evading the host's innate immune defenses, possibly through enhanced inhibition of apoptosis via proteins like CNP058, which can bind and neutralize a broad range of pro-death Bcl-2 proteins [5]. Strains lacking these genetic markers may be more likely to cause only the self-limiting cutaneous form.

2. Host Factors: Host species, age, immune status, and concurrent infections are paramount. As noted, passerines are at highest risk, but even within passerines, canaries appear exquisitely sensitive. Young, immunologically naïve birds are at greater risk than adults with prior exposure or vaccination. Immunosuppression, whether from stress, malnutrition, or concurrent disease, dramatically increases susceptibility. The Lebanese outbreak provided direct evidence of this: two of the seven autopsied canaries were co-infected with Mycoplasma gallisepticum [6]. This bacterial pathogen is a well-known immunosuppressant and respiratory pathogen in birds. The synergy between CNPV and M. gallisepticum likely accelerated the disease course and enhanced mortality, a critical consideration for controlling outbreaks on multi-pathogen farms. Furthermore, the development of systemic disease is hypothesized to result from a combination of specific viral strain variations and host factors, possibly including genetic predispositions or defects in the innate immune pathways [1]. The cGAS/IFI16-STING-type I IFN pathway and the AIM2 inflammasome are critical for host defense against CNPV [4]; any deficiency in these pathways could predispose an individual to disseminated infection.

3. Environmental and Management Factors: Environmental conditions that favor vector proliferation, warmth, standing water, and vegetation, are fundamental risk factors for CNPV transmission [15]. In captive settings, high stocking density, poor ventilation, and inadequate sanitation create a high-pathogen load environment that facilitates both vector-borne and direct transmission. Weak biosecurity, such as the failure to quarantine new arrivals, is a notorious risk factor for introducing exotic strains into established flocks [6]. The Lebanese outbreak was directly linked to the smuggling of pet birds across borders, illustrating a critical anthropogenic risk factor for the global spread of CNPV variants [6]. Vaccination status is another key modifiable risk factor. While commercial vaccines exist, they are not universally used, and their efficacy can be compromised by the emergence of new viral variants [15]. The use of CNPV strains as vaccine vectors has, ironically, introduced a theoretical risk of recombination between vaccine and field strains, although this is considered very low due to the abortive nature of the vector in mammals. However, in birds, the co-circulation of multiple avipoxvirus strains could lead to genetic reassortment or recombination, potentially generating novel strains with altered host range or virulence.

In summary, the epidemiology of CNPV is a dynamic process shaped by the genetic plasticity of the virus, the inherent susceptibility of passerine hosts, the ubiquity of arthropod vectors, and the profound influence of human activities like trade and captive management practices. The virus's capacity to cause devastating outbreaks in naïve passerine populations, coupled with its documented ability to cause systemic disease across a broader avian host range [1], underscores its significance as a pathogen that demands vigilant surveillance and robust biosecurity. The identification of the B1 subclade as a high-risk pathotype [1] provides a molecular target for diagnostic surveillance, while the continued emergence of CNPV in backyard and commercial flocks [15] emphasizes the need for integrated control strategies that address both viral and vector biology.

Clinical Manifestations and Pathological Patterns in Avian Hosts

The clinical expression of canarypox virus (CNPV) infection in avian hosts presents a spectrum of disease that ranges from localized, self-limiting epithelial proliferations to fulminant systemic dissemination with high mortality. Understanding this spectrum is critical for clinicians, diagnosticians, and epidemiologists, particularly given the virus’s host restriction primarily to passeriform species and its capacity for devastating outbreaks in captive breeding and aviary settings. The pathological patterns observed are not merely incidental; they reflect fundamental viral–host interactions at the cellular level, including viral tropism for histiocytic cells, the capacity for immune evasion, and the influence of strain-specific virulence determinants.

Classic Cutaneous and Diphtheritic Forms

The traditional dichotomy of avian poxvirus infections, the cutaneous (“dry pox”) and diphtheritic (“wet pox”) forms, is well-established in the literature and serves as the foundation for clinical classification [1, 15]. In canaries (Serinus canaria domesticus) and other passerines, the cutaneous form typically manifests as proliferative, nodular lesions on the unfeathered skin of the eyelids, cere, beak commissures, feet, and caudal regions. These lesions result from marked hyperplasia and hypertrophy of epidermal keratinocytes, accompanied by the pathognomonic formation of Bollinger bodies, eosinophilic, intracytoplasmic inclusion bodies that represent sites of viral replication and assembly [6, 15]. In a documented outbreak among canaries in Lebanon, affected birds exhibited thickened eyelids and scab-like lesions at the beak, feet, and caudal regions, with death occurring rapidly, within five to six days of symptom onset, and mortality reaching approximately 50% across multiple breeding farms [6]. This rapid clinical course and high case fatality rate underscore the heightened susceptibility of canaries compared to many galliform hosts, in which cutaneous pox is often more protracted and less lethal.

The diphtheritic form, by contrast, involves the mucous membranes of the upper respiratory tract, oropharynx, and upper gastrointestinal tract. Lesions appear as raised, caseous plaques composed of necrotic epithelium, fibrin, and inflammatory exudate, which can obstruct the glottis, nares, or esophagus, leading to respiratory distress, anorexia, and secondary bacterial infections [1, 15]. In canaries, the diphtheritic form may be particularly severe due to the small caliber of the upper airway; obstructive lesions can rapidly compromise breathing. It is critical to note that these two forms are not mutually exclusive. Mixed presentations, wherein both cutaneous nodules and diphtheritic plaques are present in the same individual, are frequently observed, especially in severe outbreaks or in immunologically naïve populations [1].

Systemic Visceral Involvement: A Distinct Pathological Entity

While historically considered rare, systemic dissemination of canarypox virus to visceral organs is now recognized as a clinically significant and likely underdiagnosed manifestation. Sinnott and colleagues (2023) provided a landmark analysis of systemic avian poxvirus over a 20-year period at a zoological institution, identifying 22 systemic cases among 151 total poxvirus diagnoses. This 14.6% prevalence indicates that systemic disease is far from exceptional in susceptible species [1]. The gross pathological findings in these systemic cases were strikingly consistent: soft, white to tan nodules scattered throughout the parenchyma of the liver, spleen, and kidneys. These lesions were distinct from the epithelial proliferation seen in cutaneous pox, suggesting a fundamentally different pathobiology [1].

Histopathologically, two distinct patterns emerged from this analysis. The first pattern was characterized by widespread, multifocal histiocytic inflammation in visceral organs, with individual histiocytes containing large, eosinophilic, intracytoplasmic viral inclusions. This pattern suggests that the virus is capable of infecting and replicating within tissue-resident macrophages or dendritic cells, using these cells as vehicles for hematogenous or lymphatic dissemination to distant organ systems. The second pattern involved severe, localized cutaneous or diphtheritic lesions, often extensive and necrotic, with poxvirus-like inclusions identified within dermal and subepithelial histiocytes [1]. Critically, in situ hybridization targeting the core P4b protein gene confirmed the presence of viral DNA within histiocytes in both patterns, firmly establishing the histiocyte as a key cellular target during systemic spread [1].

Molecular Determinants of Systemic Pathogenesis

The ability of canarypox virus to cause systemic disease appears to be linked, at least in part, to specific viral genetic determinants. Sequencing of the core P4b protein gene from all systemic cases in the aforementioned study grouped these viruses into cluster 2 of the B1 subclade of canarypox viruses, suggesting that this particular phylogenetic lineage possesses an enhanced capacity for visceral dissemination [1]. Furthermore, sequence analysis of the reticuloendotheliosis virus (REV) long terminal repeat (LTR) flanking region revealed that all systemic pox cases shared an identical sequence to a previously described “condorpox virus” isolated from an Andean condor with systemic pox [1]. This finding is particularly intriguing because it implicates a possible role for REV integration in modulating viral pathogenesis. Integrated REV LTR sequences are known to act as transcriptional enhancers in some avipoxviruses, and their presence may upregulate adjacent viral genes involved in immune evasion or cellular tropism, thereby facilitating systemic spread. The convergence of the B1 subclade genotype and the specific REV LTR flanking sequence in systemic cases points to a multigenic basis for virulence, likely involving both core viral genes and acquired genetic elements.

Host Susceptibility and Environmental Co-Factors

The expression of systemic disease is not purely a function of viral strain; host and environmental factors are critical co-determinants. The canarypox outbreak described by Shaib and Barbour (2018) occurred in a context of suspected smuggling of pet birds across borders, introducing a virulent strain into a naïve population [6]. Concurrent infections likely exacerbate disease severity. In that same outbreak, PCR analysis revealed that two birds were co-infected with Mycoplasma gallisepticum, a respiratory pathogen that can cause airsacculitis and immunosuppression [6]. The observation of turbid air sacs in one autopsied bird, with hyperplasia and heterophil infiltration in the air sacs, is suggestive of synergistic pathology between CNPV and mycoplasmosis [6]. Immunosuppression, whether from concurrent infection, nutritional stress, or overcrowding, almost certainly predisposes birds to more severe, systemic forms of poxviral disease.

Histopathological Spectrum and Cellular Tropism

The histopathological lesions of canarypox in avian hosts are characterized by epidermal hyperplasia, acanthosis, and ballooning degeneration of keratinocytes. The hallmark Bollinger bodies are large (up to 30 µm), rounded, eosinophilic inclusions that push the host cell nucleus to the periphery [6, 15]. In the diphtheritic form, the submucosa is infiltrated by heterophils, macrophages, and lymphocytes, with extensive necrosis and fibrin deposition. The visceral form expands this histopathological repertoire to include multifocal granulomatous inflammation in the liver, spleen, and kidneys, with histiocytes serving as the primary cellular reservoir for viral replication [1]. This shift in tropism, from epithelial cells to histiocytes, represents a critical pathogenetic step, enabling the virus to evade the immune system and disseminate widely. The World Organisation for Animal Health (WOAH) recognizes avian poxvirus as a notifiable disease in certain contexts, particularly in endangered species and commercial poultry, underscoring the importance of accurate histopathological and molecular diagnosis in suspect systemic cases.

Zoonotic and Economic Considerations

It must be emphasized that canarypox virus, unlike some orthopoxviruses, is not considered zoonotic. The virus is highly host-restricted, and no cases of human infection have been documented. However, the economic and conservation impacts are substantial. In commercial canary breeding operations, mortality rates of 50% or higher, as reported in the Lebanese outbreak, represent catastrophic production losses [6]. Among zoo and aviary populations, systemic pox can devastate collection of rare and valuable passerines. The recognition that systemic disease is associated with a specific subclade (B1) and a particular REV integration pattern [1] raises the possibility of molecular surveillance for hypervirulent strains, allowing preemptive quarantine and biosecurity measures.

In summary, the clinical manifestations of canarypox virus in avian hosts range from benign cutaneous nodules to lethal systemic dissemination. The cutaneous and diphtheritic forms reflect classic epithelial tropism, while systemic disease involves a fundamental shift to histiocyte infection, enabled by specific viral genetic determinants, notably membership in the B1 subclade and the presence of REV LTR sequences, and potentiated by host immunosuppression and environmental stressors. Accurate diagnosis requires histopathological examination for Bollinger bodies and, increasingly, molecular confirmation via PCR and sequencing of the P4b gene to identify strains with systemic potential. These insights into the pathological patterns of CNPV are essential for developing effective biosecurity protocols, guiding vaccination strategies in endemic regions, and informing the management of captive passerine populations.

Diagnostic Approaches for Canarypox Virus: Histopathology, In Situ Hybridization, and Molecular Assays

The accurate and definitive diagnosis of canarypox virus (CNPV) infection, particularly in the context of differentiating it from other avian poxviruses and systemic viral diseases, relies on a multi-modal diagnostic approach. While clinical presentation, ranging from the classic cutaneous “dry” pox lesions to the more severe diphtheritic “wet” form, can provide a strong index of suspicion, definitive diagnosis requires laboratory confirmation. This section provides an exhaustive analysis of the three cornerstone diagnostic modalities: histopathology, in situ hybridization (ISH), and molecular assays, with a focus on their mechanistic underpinnings, interpretive nuances, and comparative utility in both clinical and research settings.

Histopathological Examination: The Gold Standard for Morphological Confirmation

Histopathology remains the foundational diagnostic tool for avian poxvirus infections, including those caused by CNPV. The hallmark of poxvirus infection is the presence of characteristic intracytoplasmic inclusion bodies, known as Bollinger bodies, which represent aggregates of mature virions (elementary bodies) within infected epithelial cells. In a landmark retrospective study of 151 avian poxvirus cases over a 20-year period at a zoological institution, Sinnott et al. (2023) delineated two distinct histopathologic patterns associated with systemic CNPV infection [1]. The first pattern was characterized by widespread histiocytic inflammation in visceral organs, most notably the liver, spleen, and kidneys, with intrahistiocytic viral inclusions. The second pattern involved severe, localized dry or wet pox lesions, with poxvirus-like inclusions observed within dermal and subepithelial histiocytes [1]. This distinction is clinically critical, as the systemic form is rare but carries a far graver prognosis.

In the cutaneous form, histopathological examination of biopsied skin nodules reveals marked epidermal hyperplasia (acanthosis) and hyperkeratosis. The underlying dermis is infiltrated by heterophils (the avian equivalent of neutrophils) and macrophages. The pathognomonic Bollinger bodies are large, eosinophilic, round to oval intracytoplasmic inclusions that displace the host cell nucleus. In a study of a CNPV outbreak in Lebanon, Shaib and Barbour (2018) reported that histopathological examination of skin lesions from five of seven autopsied canaries revealed hyperplasia, heterophil infiltration, and Bollinger body formation, confirming the diagnosis [6]. Importantly, the same study noted that one bird exhibited turbid airsacs with hyperplasia and heterophil infiltration, but without inclusion bodies, highlighting that a negative finding on routine histopathology does not rule out infection, particularly in atypical or early cases [6].

For the diphtheritic form, histopathology of mucosal lesions from the oropharynx, trachea, or esophagus shows similar epithelial hyperplasia and necrosis, with a fibrino-necrotic exudate admixed with heterophils and macrophages. The inclusions are often more difficult to identify in these cases due to extensive tissue necrosis and secondary bacterial colonization. The systemic form, as described by Sinnott et al. (2023), presents a unique diagnostic challenge. Grossly, soft white nodules are scattered throughout the liver, spleen, and kidneys [1]. Microscopically, the key finding is the presence of histiocytic inflammation with intrahistiocytic viral inclusions, rather than the classic epithelial inclusions seen in the cutaneous form [1]. This suggests that certain CNPV strains, particularly those belonging to the B1 subclade, have a tropism for cells of the monocyte/macrophage lineage, enabling systemic dissemination [1]. The differential diagnosis for systemic histiocytic inflammation with inclusions includes other viral infections such as reticuloendotheliosis virus (REV) and Marek’s disease virus, underscoring the need for ancillary molecular testing.

In Situ Hybridization: Localizing Viral Nucleic Acid Within Tissues

While histopathology provides morphological evidence of viral infection, it cannot definitively distinguish between different poxvirus species or confirm the presence of viral nucleic acid in the absence of visible inclusions. In situ hybridization (ISH) bridges this gap by allowing for the direct visualization of viral DNA or RNA within the context of intact tissue architecture. Sinnott et al. (2023) employed ISH targeting the core P4b protein gene of avipoxviruses to confirm the presence of poxvirus DNA within histiocytes in both histopathologic patterns of systemic disease [1]. This technique is particularly powerful because it can detect viral nucleic acid even in cells that do not contain morphologically identifiable Bollinger bodies, thereby increasing diagnostic sensitivity.

The P4b gene (also known as the fpv167 locus) is a highly conserved core protein gene within the Avipoxvirus genus, making it an ideal target for genus-specific ISH probes. The ISH signal appears as a distinct, punctate, dark blue or brown precipitate (depending on the chromogen used) localized to the cytoplasm of infected cells. In the context of systemic CNPV infection, ISH confirmed that the histiocytes infiltrating the liver, spleen, and kidney were the primary cellular reservoirs of the virus [1]. This finding is biologically significant because it suggests that the virus is not merely passively present in the blood but is actively replicating within tissue-resident or recruited macrophages, a mechanism that facilitates systemic spread and immune evasion.

The utility of ISH extends beyond mere confirmation. It allows for the semi-quantitative assessment of viral load within specific tissue compartments and can be used to study the pathogenesis of CNPV in experimental models. For instance, in vaccine development studies using recombinant canarypox vectors (ALVAC), ISH can be used to track the persistence and clearance of the vector from injection sites and draining lymph nodes. This is particularly relevant given that ALVAC-based vaccines, such as those used for feline leukemia virus (FeLV) [2, 9, 13], canine distemper virus (CDV) [3, 11], and equine influenza virus (EIV) [7, 8, 14], are live recombinant vectors that must replicate transiently to induce an immune response. ISH provides a direct method to confirm that the vector is not causing uncontrolled, lytic infection in the host.

Molecular Assays: PCR, Sequencing, and Phylogenetic Analysis

Molecular assays, particularly polymerase chain reaction (PCR), have become the most sensitive and specific tools for the diagnosis of CNPV. They offer several advantages over histopathology and ISH, including the ability to detect viral nucleic acid in samples with low viral loads, degraded tissue, or when only non-invasive samples (e.g., swabs of lesions, feather pulp) are available. The most commonly targeted gene for CNPV detection is the core P4b protein gene, which is highly conserved across the Avipoxvirus genus but contains variable regions that allow for species and clade differentiation.

In the Lebanese outbreak study, Shaib and Barbour (2018) performed PCR analysis targeting the fpv167 gene (the P4b homolog) on specimens taken from the skin and feet of affected canaries. All analyzed birds were positive, and subsequent sequencing of the amplified product revealed 100% similarity with the Iranian canary pox isolate IR/H913/14 [6]. This level of sequence identity is indicative of a common source of introduction, likely linked to the illegal smuggling of pet birds across borders [6]. This case highlights the critical role of PCR and sequencing in molecular epidemiology, enabling the tracking of viral spread across geographic regions and the identification of potential biosecurity breaches.

For systemic CNPV infections, Sinnott et al. (2023) employed a dual PCR strategy targeting both the P4b core protein gene and the reticuloendothelial virus long terminal repeat (REV LTR) flanking region [1]. The inclusion of the REV LTR flanking region is a sophisticated approach designed to detect potential recombination events between avipoxviruses and retroviruses, a phenomenon that has been implicated in the emergence of highly pathogenic strains. Remarkably, all systemic pox cases in their study had identical sequences of the REV LTR flanking region, which matched a previously described condorpox virus isolated from an Andean condor with systemic pox [1]. This finding suggests that the acquisition of REV LTR sequences may be a common mechanism driving systemic virulence in avipoxviruses across different avian orders.

Phylogenetic analysis of the P4b gene sequences from the systemic cases revealed that they all grouped into cluster 2 of the B1 subclade of canarypox viruses [1]. This is a critical finding, as it demonstrates that not all CNPV strains are created equal; specific genetic lineages are associated with a higher risk of systemic dissemination. The B1 subclade is now recognized as a distinct genetic group that may possess unique virulence factors, such as the CNP058 Bcl-2 mimic protein, which has been shown to inhibit apoptosis in host cells [5]. By blocking premature host cell death, CNP058 allows the virus to complete its replication cycle and spread more effectively [5]. The combination of PCR, sequencing, and phylogenetic analysis thus provides a powerful framework for understanding the molecular determinants of CNPV pathogenesis.

The choice of PCR target can also influence diagnostic sensitivity and specificity. While the P4b gene is excellent for genus-level detection, it may not distinguish between closely related avipoxviruses such as fowlpox virus (FWPV) and CNPV. For species-specific identification, targeting the fpv140 (host range) gene or the fpv126 (reticuloendotheliosis virus integration) region may be necessary. Furthermore, real-time quantitative PCR (qPCR) assays can be developed to quantify viral load in tissues or blood, which is particularly useful for monitoring the progression of systemic disease or the efficacy of antiviral treatments. The World Organisation for Animal Health (WOAH) recognizes PCR as a prescribed test for the diagnosis of avian poxvirus infections, and its use is recommended for confirmatory testing in suspected outbreaks, especially in commercial poultry and captive exotic bird collections.

Comparative Utility and Diagnostic Algorithm

In a comprehensive diagnostic algorithm, histopathology should be considered the first-line test when tissue biopsies or necropsy specimens are available. The identification of Bollinger bodies in epithelial or histiocytic cells provides a rapid, cost-effective presumptive diagnosis. However, given the potential for false negatives in early or atypical cases, and the inability to differentiate between CNPV and other avipoxviruses, histopathology should be followed by molecular confirmation. ISH is best reserved for research applications or cases where it is critical to localize the virus within specific cell types, such as in studies of systemic pathogenesis [1] or vaccine vector biology.

For live birds, PCR on swab samples (oral, conjunctival, or cutaneous lesion swabs) is the preferred diagnostic method due to its high sensitivity and non-invasive nature. The detection of CNPV DNA in the absence of clinical signs may indicate subclinical infection or environmental contamination, and results should be interpreted in conjunction with clinical and serological findings. The use of sequencing and phylogenetic analysis is essential for outbreak investigations, as it can identify the source of infection, track viral evolution, and inform vaccine strain selection. Given the zoonotic potential of related poxviruses is low, but the economic impact of CNPV on the canary and passerine trade is substantial, adherence to WOAH guidelines for diagnostic testing is strongly recommended to prevent international spread.

Immunological Responses and Canarypox-Vectored Vaccine Applications

The canarypox virus (CNPV), a member of the genus Avipoxvirus within the family Poxviridae, has emerged as a preeminent platform for vectored vaccine development across multiple vertebrate species. Unlike replication-competent mammalian poxviruses, canarypox virus exhibits an elegant and clinically crucial evolutionary adaptation: a profound host range restriction that permits efficient infection and antigen expression in mammalian cells without producing infectious progeny. This abortive replication cycle, most notably exemplified by the attenuated ALVAC strain, renders the vector intrinsically safe while preserving the immunological potency of a live viral immunogen. The immunological responses engendered by canarypox-vectored vaccines are multifaceted, encompassing rapid innate activation through cytosolic DNA sensing pathways, potent induction of type I interferon (IFN) responses, robust T-cell polarization, and durable humoral immunity. These properties have been harnessed across a remarkable spectrum of veterinary and human pathogens, including rabies virus, canine distemper virus (CDV), feline leukemia virus (FeLV), equine influenza virus (EIV), Hendra virus (HeV), Leishmania infantum, and even neoplastic diseases such as feline injection-site sarcomas.

Innate Immune Recognition and Inflammasome Activation by the ALVAC Vector

The immunogenicity of canarypox-based vectors is fundamentally rooted in their capacity to engage the innate immune system with exceptional potency. Seminal work by Liu et al. elucidated a novel mechanism wherein ALVAC triggers robust inflammasome activation in both human and murine antigen-presenting cells (APCs) through the absent in melanoma 2 (AIM2) sensor [4]. This pathway is not merely incidental but represents a critical axis of the vector's adjuvant activity. ALVAC infection stimulates the cyclic GMP-AMP synthase (cGAS)/interferon gamma-inducible protein 16 (IFI16)–stimulator of interferon genes (STING)–type I IFN signaling cascade, which serves to "prime" the inflammasome by upregulating AIM2 expression. The subsequent detection of cytosolic double-stranded DNA, likely derived from the replicating viral genome, by AIM2 leads to the assembly of the inflammasome complex, caspase-1 activation, and the maturation of interleukin-1β (IL-1β) and interleukin-18 (IL-18) [4]. This differential capacity to activate the AIM2 inflammasome distinguishes ALVAC from other viral vectors, such as human adenovirus serotype 5 (Ad5), which fails to stimulate the STING–type I IFN pathway and consequently cannot provide the necessary priming signals for inflammasome activation [4]. This mechanistic divergence likely contributes to the distinct immunological profiles observed with these vectors in clinical settings.

Complementing this inflammasome axis, ALVAC also exerts a profound influence on natural killer (NK) cell biology. Ryan et al. demonstrated that ALVAC immunization induces early interferon-gamma (IFN-γ) production, with NK cells identified as the principal cellular source in vivo [12]. Immuno-depletion of NK cells prior to ALVAC administration abrogated this early IFN-γ burst, indicating a non-redundant role for these innate lymphocytes in the vector's mode of action [12]. The functional consequence of this NK cell-derived IFN-γ is the enhancement of T-helper type 1 (Th1) polarization, evidenced by augmented antigen-specific IgG2a responses when ALVAC is combined with protein antigens [12]. Concurrently, ALVAC directly activates dendritic cells (DCs), as demonstrated by the upregulation of maturation markers CD40, CD80, and CD86, alongside the secretion of chemokines CXCL10 and CCL2 [12]. This coordinated activation of NK cells and DCs establishes a positive feedback loop that amplifies cell-mediated immunity, a hallmark of the canarypox vector platform.

Viral Countermeasures and Apoptosis Modulation

The immunogenicity of any viral vector is inextricably linked to its ability to balance replication and host cell survival. Canarypox virus has evolved sophisticated mechanisms to subvert premature host cell apoptosis, thereby ensuring sufficient time for antigen production and immune recognition. The CNP058 protein, identified through genomic sequencing of CNPV, is a structural and functional mimic of cellular B-cell lymphoma 2 (Bcl-2) family pro-survival proteins [5]. Anasir et al. demonstrated that CNP058 binds with high-to-moderate affinity to a broad spectrum of host pro-apoptotic Bcl-2 proteins, including the effector proteins Bak and Bax, as well as multiple BH3-only sensitizers such as Bim, Bid, Bmf, Noxa, Puma, and Hrk [5]. Structural analysis of the CNP058–Bim BH3 complex revealed that CNP058 adopts the canonical Bcl-2 fold, utilizing its conserved hydrophobic groove to sequester pro-death ligands [5]. Functional studies confirmed that CNP058 is a potent inhibitor of ultraviolet (UV)-induced apoptosis in cell culture [5]. This anti-apoptotic activity is strategically advantageous: by preventing the premature destruction of infected cells, CNP058 allows for sustained antigen synthesis and prolonged exposure of the immune system to vector-encoded immunogens, thereby enhancing the magnitude and durability of the adaptive response.

Humoral and Cellular Immune Responses to Canarypox-Vectored Vaccines

The immunological outputs of canarypox-vectored vaccination are highly consistent across a diverse array of target pathogens, typically characterized by the induction of neutralizing antibodies, IFN-γ-producing T cells, and long-lived memory responses. In the context of rabies virus, the ALVAC platform has demonstrated remarkable efficacy. Weidinger et al. evaluated the concurrent administration of Purevax Rabies and Purevax FeLV in cats and found that all animals achieved World Organisation for Animal Health (WOAH)-compliant antibody titers (≥0.5 IU/mL) after a one-year booster, with no significant difference in geometric mean titers between concurrent and separate administration groups [2]. More recently, Meng et al. developed an ALVAC-based rabies virus-like particle (VLP) vaccine (ALVAC-RABV-VLP) using CRISPR/Cas9 gene editing, which induced potent activation of dendritic cells, follicular helper T cells (Tfh), and the germinal center (GC)/plasma cell axis in mice, resulting in 100% survival upon lethal challenge [17]. In dogs and cats, a single dose of this VLP vaccine elicited stronger and longer-lasting antibody responses than a commercial inactivated rabies vaccine [17], underscoring the potential of the canarypox platform to simplify vaccination regimens for zoonotic disease control.

The application of canarypox vectors to canine distemper virus vaccination represents one of the earliest and most successful demonstrations of this technology. The recombinant ALVAC-CDV vaccine, expressing the CDV hemagglutinin (H) and fusion (F) glycoproteins, has been extensively validated. In a landmark study by Pardo et al., specific-pathogen-free (SPF) Beagle pups vaccinated with a canarypox-CDV combination vaccine were completely protected (0% morbidity and mortality) against virulent CDV challenge, whereas 100% of control dogs succumbed to disease [11]. This protection was achieved even at a dose 40 times lower than the commercial recommendation, and the vaccine did not interfere with the seroconversion to concurrent modified-live virus components [11]. Building upon this foundation, Gong et al. employed CRISPR/Cas9 technology to engineer a more efficient recombinant ALVAC-CDV-M-F-H/C5- strain that co-expresses the matrix (M), H, and F proteins, facilitating the assembly of CDV virus-like particles [3]. In minks and foxes, this novel construct induced faster seroconversion and higher rates of antibody positivity compared to the parental strain, even before a second booster vaccination [3]. This demonstrates that the genetic architecture of the insert can be optimized to enhance the kinetics and magnitude of the immune response.

For feline leukemia virus, the canarypox-vectored PureVax FeLV vaccine has been a subject of considerable clinical investigation. However, comparative efficacy studies have revealed important nuances. Patel et al. demonstrated that while the canarypox-vectored FeLV vaccine provided partial protection against virulent challenge, with a preventable fraction of 45%, an inactivated adjuvanted whole-virus vaccine (Nobivac feline 2-FeLV) conferred 100% protection against persistent antigenemia [9]. The canarypox-vectored vaccine group showed significantly higher proviral DNA and plasma viral RNA loads compared to the adjuvanted vaccine group [9]. These findings underscore that not all vaccine platforms are equivalent for all pathogens; the immunological requirements for sterilizing immunity against FeLV likely demand a different balance of humoral and cellular responses than what the canarypox vector alone may provide in this specific context. Conversely, in the realm of cancer immunotherapy, the ALVAC platform expressing feline interleukin-2 (IL-2) has demonstrated remarkable therapeutic potential. Jas et al. reported that adjunctive treatment with ALVAC IL-2 in cats undergoing surgery and brachytherapy for fibrosarcoma significantly extended the median time to relapse to over 730 days in the low-dose group, compared to 287 days in controls, and reduced the risk of relapse by 65% at two years [16]. This application highlights the versatility of the vector as a delivery system for immunomodulatory cytokines, not merely foreign antigens.

Cross-Protection, Adjuvant Synergy, and Prime-Boost Strategies

The immunological breadth of canarypox-vectored vaccines is further enhanced by their compatibility with heterologous prime-boost regimens and synergistic adjuvant combinations. Abbehusen et al. evaluated a novel vaccination strategy against canine visceral leishmaniosis using a priming dose of plasmid DNA encoding Lutzomyia longipalpis salivary proteins LJM17 or LJL143, followed by two booster doses of recombinant canarypox virus expressing the same antigens [18]. This heterologous approach induced strong humoral responses and a pro-inflammatory cytokine profile characterized by elevated IFN-γ, tumor necrosis factor (TNF), IL-2, IL-6, IL-7, IL-15, IL-18, CXCL10, and GM-CSF in dogs immunized with LJM17 [18]. Importantly, this profile was consistent with protective immunity against Leishmania infantum, suggesting that the canarypox vector is an effective boosting agent for DNA-primed responses.

In the equine domain, the canarypox-vectored equine influenza vaccine (ProteqFlu) has demonstrated both clinical efficacy and the capacity for cross-reactive humoral immunity. El-Hage et al. showed that horses vaccinated with ProteqFlu developed haemagglutination inhibition (HI) antibodies cross-reactive not only to the vaccine strains but also to the heterologous outbreak strain A/equine/Sydney/07, which belonged to a different lineage [8]. This cross-reactivity provides a mechanistic explanation for the clinical protection observed in Australian horses despite a strain mismatch. Furthermore, the combination of the canarypox vector with potent adjuvants can amplify its immunogenicity. Lee et al. demonstrated that co-administration of a canarypox-based EIV vaccine with monophosphoryl lipid A (MPL) and polyinosinic-polycytidylic acid (poly I:C) significantly enhanced serum IgG and HI titers, maintained antibody levels for up to 24 weeks, and increased the frequencies of CD4⁺ and CD8⁺ T cells, as well as memory B cell responses in bone marrow and lymph nodes [14]. Similarly, concurrent vaccination with canarypox-EIV and inactivated equine herpesvirus (EHV) vaccines enhanced IFN-γ production without compromising humoral responses [7], indicating that the vector does not exhibit overt immunological interference with other vaccine components.

The capacity for heterologous prime-boost regimens has also been explored in the context of influenza. Lee et al. demonstrated that concurrent administration of a recombinant canarypox EIV vaccine and an inactivated bivalent EHV vaccine significantly increased IFN-γ production without compromising humoral responses, suggesting that the vector's cellular immunogenicity can be harnessed even in the presence of other vaccines [7]. This immunological flexibility is critical for practical field applications where polyvalent vaccination schedules are common.

Zoonotic Threat Mitigation and One Health Applications

The canarypox vector has proven instrumental in developing vaccines against emerging zoonotic pathogens of significant public health concern. Hendra virus, a biosafety level 4 (BSL-4) paramyxovirus transmitted from pteropid bats to horses and then to humans, has a case fatality rate exceeding 50% in humans. Guillaume-Vasselin et al. developed a canarypox-based vaccine expressing the Hendra virus attachment glycoprotein (G) and fusion protein (F) and evaluated it in hamsters and ponies [10]. In hamsters, the higher tested dose of the vaccine efficiently protected against clinical disease and mortality, prevented oropharyngeal virus shedding, and abrogated viral RNA and antigen detection in tissues [10]. Notably, some animals immunized with a lower dose were protected in the absence of detectable neutralizing antibodies, implicating cellular immunity as a critical protective mechanism [10]. In ponies, the vaccine induced strong seroneutralizing titers against both Hendra virus and the closely related Nipah virus, suggesting the potential for cross-protection against henipavirus infection [10]. This study exemplifies the One Health relevance of the canarypox platform, offering a vaccine that protects both horses (as sentinel and amplifying hosts) and humans (through reduced zoonotic spillover).

The utility of canarypox vectors extends to the control of pathogens in wildlife and captive exotic species. Systemic avian poxvirus infections, while historically considered rare, have been increasingly documented in zoological collections. Sinnott et al. described systemic canarypox infections in 22 of 151 avian poxvirus cases over a 20-year period at a zoological institution, with molecular characterization revealing that all systemic cases grouped into cluster 2 of the B1 subclade of canarypox viruses [1]. The pathology included widespread histiocytic inflammation in visceral organs with intrahistiocytic viral inclusions, and in situ hybridization confirmed the presence of poxvirus DNA within histiocytes [1]. Although this study did not evaluate vaccination, it highlights the pathogenic potential of certain CNPV strains and underscores the need for effective immunization strategies in susceptible avian populations.

Poultry and Conservation Applications

Beyond mammalian vaccinology, the canarypox virus has been explored as a vaccine vector for avian species. Zanetti et al. engineered recombinant canarypox viruses expressing the VP2 protein of infectious bursal disease virus (IBDV) and demonstrated that these constructs induced IBDV-neutralizing antibodies when inoculated into specific pathogen-free (SPF) chickens [19]. This proof-of-concept study established that the canarypox platform, despite its natural host range being passeriform birds, can effectively deliver immunogens to galliform species, broadening its applicability in poultry vaccinology. Concurrently, the use of canarypox as a vector is distinguished from fowlpox virus (FWPV) vectors, which are more commonly employed in poultry but may face issues of pre-existing immunity in vaccinated flocks [15].

Immunological Memory and Longevity of Protection

The durability of immune responses elicited by canarypox-vectored vaccines is a critical attribute for practical field use. The formation of long-lived plasma cells and memory B cells is dependent on the germinal center reaction, which is efficiently induced by ALVAC. Meng et al. demonstrated that ALVAC-RABV-VLP

Emerging Strains and Genetic Diversity: The B1 Subclade and Systemic Infections

The canonical understanding of avian poxvirus pathogenesis, long delineated into the self-limiting cutaneous “dry” form and the more severe diphtheritic “wet” form, has been fundamentally challenged by the recognition of systemic disease. Historically considered a rare event, the visceral dissemination of avipoxviruses to internal organs such as the liver, spleen, and kidneys represents a paradigm shift in our comprehension of host-virus dynamics within the Avipoxvirus genus. Seminal work by Sinnott and colleagues (2023), drawing upon a two-decade retrospective analysis at a major zoological institution, has crystallized this phenomenon, revealing that systemic infection is not merely an incidental finding but a distinct pathological entity with a strong molecular signature [1]. This section dissects the emergence of the B1 subclade of canarypox viruses (CNPV) as the principal etiological agent of these systemic infections, exploring the genetic underpinnings, the histopathological mechanisms of visceral spread, and the complex interplay of viral strain, host susceptibility, and environmental context that precipitates this often-fatal outcome.

Phylogenetic Framework and the Identification of the B1 Subclade

The genetic diversity among avipoxviruses is vast, with host range traditionally used as a crude taxonomic filter: fowlpox-like viruses in Galliformes, canarypox-like viruses in Passeriformes, and distinct clades in Psittaciformes [15]. However, molecular phylogenetics, particularly targeting the highly conserved core P4b protein gene, has revealed a more intricate substructure. The study by Sinnott et al. (2023) performed a critical molecular dissection of 22 systemic avian poxvirus cases out of a total of 151 diagnosed over 20 years [1]. By sequencing the P4b gene, the authors demonstrated that all 22 systemic cases grouped unequivocally into cluster 2 of the B1 subclade of canarypox viruses [1]. This finding is seminal, as it provides the first comprehensive evidence linking a specific, genetically defined viral lineage to a drastically different clinical outcome. The B1 subclade is not a monolithic entity; it contains variable strains, and cluster 2 appears to harbor a genetic architecture that confers, or correlates with, an enhanced capacity for systemic invasion. This phylogenetic segregation suggests that the capacity for visceral spread is not a universal trait of CNPV but is largely restricted to a specific evolutionary branch, a hypothesis further supported by the absence of systemic cases attributed to other avipoxvirus clades in the same study population [1].

Further genetic evidence solidifies this association. The same study analyzed the reticuloendotheliosis virus (REV) long terminal repeat (LTR) flanking region, a genetic element known to be integrated into the genomes of many avipoxviruses and often associated with altered virulence [1]. Remarkably, the REV LTR flanking region sequences from all systemic pox cases were identical to a previously described condorpox virus isolated from an Andean condor (Vultur gryphus) that succumbed to systemic pox [1]. This genetic conservation across different avian orders (Passeriformes and Accipitriformes) is profound. It implies that the integration or specific conformation of this REV LTR element may be a stable, transmissible virulence determinant. The REV LTR is hypothesized to act as a promoter or enhancer, potentially dysregulating the expression of adjacent viral host-range or immune-modulatory genes. The fact that this exact genetic motif is shared between a systemic condorpox virus and systemic canarypox viruses indicates that the B1 subclade, cluster 2 viruses, carrying this specific REV LTR signature, represent a particularly pathogenic lineage capable of overcoming anatomical and immunological barriers that normally confine avipoxviruses to the epithelium.

Pathobiology of Systemic Spread: A Tale of Two Histopathological Patterns

The clinical significance of B1 subclade infection is starkly illustrated by the systemic dissemination it engenders. Grossly, these infections manifest as characteristic soft, white-to-tan nodules of necrosis and inflammation scattered throughout the parenchyma of the liver, spleen, and kidneys [1]. This pattern of multifocal visceral necrosis is a clear departure from the superficial epithelial tropism of typical poxvirus infections. Histopathological analysis by Sinnott et al. (2023) resolved this systemic disease into two distinct patterns, both driven by infection of the mononuclear phagocyte system [1].

Pattern 1: Widespread Histiocytic Inflammation. In this form, there is a diffuse, coalescing infiltration of histiocytes (tissue macrophages) within the hepatic sinusoids, splenic red pulp, and renal interstitium [1]. The critical diagnostic feature is the presence of large, intracytoplasmic, eosinophilic viral inclusions (Bollinger bodies) within these histiocytes. This pattern represents a primary infection of the reticuloendothelial system. The virus appears to have circumvented the epithelial barrier entirely, perhaps via a breach in mucosal integrity or through infection of migratory dendritic cells in the skin, which then traffic the virus to draining lymph nodes and subsequently into the bloodstream. Once in the circulation, the macrophage-rich organs (liver, spleen) become the primary targets. This pattern suggests a fundamental shift in viral tropism from epithelial cells to macrophages, likely mediated by specific viral genes within the B1 subclade that allow for productive infection and survival within these phagocytic cells. The detection of poxvirus DNA via in situ hybridization specifically within these intrahistiocytic inclusions confirmed that these cells are the primary viral reservoir in the viscera [1].

Pattern 2: Severe Localized Pox with Systemic Seeding. The second pattern is characterized by severe, locally aggressive dry or wet pox lesions at the primary site of infection (e.g., skin, oral mucosa) [1]. The viral replication at these sites is extensive, leading to massive tissue destruction and necrosis. Within the dermis and subepithelium surrounding these lesions, histiocytes laden with poxvirus inclusions are abundant [1]. This pattern suggests a "spillover" mechanism. The overwhelming local viral burden overwhelms local immune containment, allowing virus-laden macrophages to be swept into the lymphatic or vascular systems, establishing secondary foci of infection in distant organs. The distinction between these two patterns is important for understanding disease progression. Pattern 1 suggests a primary, tropism-driven systemic disease, while Pattern 2 suggests a "secondary" systemic disease arising from a catastrophic failure of local control. Both, however, converge on the same fundamental mechanism: the histiocyte acts as the vector for visceral dissemination.

Implications for Diagnosis, Surveillance, and Vaccine Safety

The identification of the B1 subclade as a genetic marker for systemic pathogenicity has immediate diagnostic and biosecurity implications. For veterinary diagnosticians and zoological pathologists, the presence of systemic granulomatous nodules in a passerine or other susceptible bird should immediately prompt molecular characterization of the P4b gene, targeting cluster 2 of the B1 subclade [1]. Routine PCR assays for avian poxvirus should now include sequencing or specific genotyping to distinguish between the common, self-limiting cutaneous strains and the potentially lethal systemic B1 variants. This is critical for outbreak management, as the detection of a systemic strain in a naïve captive population, such as a zoo breeding colony, would warrant aggressive quarantine and potentially depopulation strategies to prevent a high-mortality epizootic. The World Organisation for Animal Health (WOAH) recognizes poxvirus infections in poultry and wild birds; the emergence of highly pathogenic strains like the B1 subclade underscores the need for enhanced molecular surveillance within that framework.

Furthermore, this finding has profound implications for the safety of canarypox virus as a vaccine vector. The ALVAC strain, a plaque-purified, attenuated derivative of CNPV, is the backbone of numerous recombinant vaccines for veterinary and human use, including those against rabies, feline leukemia virus (FeLV), equine influenza, canine distemper, and even experimental HIV vaccines [2-4, 7-12, 17, 18, 20]. The safety profile of ALVAC relies on its host-range restriction, it productively infects mammalian cells but does not produce infectious progeny, ensuring it cannot cause disseminated poxvirus disease in the vaccinated host. However, the discovery that wild-type B1 subclade CNPV can cause severe, systemic disease in its natural avian host raises critical questions about the potential for recombination or reversion to virulence. While ALVAC itself has been exquisitely engineered and proven safe, the existence of highly pathogenic wild-type CNPV strains in the environment means that strict physical containment and rigorous genetic characterization of vector seed stocks are paramount. The CRISPR/Cas9-based engineering of ALVAC, while enabling the construction of more immunogenic vectors like those producing virus-like particles, also necessitates careful screening to ensure no inadvertent acquisition of virulence-associated motifs from the B1 subclade [3, 17]. The B1 subclade’s REV LTR integration, in particular, serves as a stark reminder that genome structure can dictate pathogenic potential, and that even in a non-replicating vector, the introduction of certain wild-type gene cassettes could theoretically alter the host immunological response in unpredictable ways.

In summary, the B1 subclade, and specifically its cluster 2 members, represent an emergent paradigm within avipoxvirology. These strains possess a unique genetic repertoire, likely including a specific REV LTR configuration, that enables systemic dissemination via the infection of histiocytes. This shifts the disease from a benign, self-resolving epithelial infection to a potentially fatal, multi-organ systemic disease. The discovery necessitates a re-evaluation of avipoxvirus epidemiology, moving beyond simple species-specific diagnosis to a nuanced, genotype-driven approach. It also serves as a critical case study for the inherent variability of poxvirus pathogenicity and the importance of rigorous genetic and biological characterization of wild-type strains, even those used in the development of purportedly safe live-vectored vaccines.

References

[1] Sinnott D, Burchell JT, Witte C, Burns R, Kubiski SV. Systemic avian poxvirus infections associated with the B1 subclade of canarypox virus. Veterinary Pathology-Supplement. 2023. DOI: https://doi.org/10.1177/03009858231190639

[2] Weidinger A, Bergmann M, König M, Zablotski Y, Hartmann K. Anti-rabies humoral immune response in cats after concurrent vs separate vaccination against rabies and feline leukaemia virus using canarypox-vectored vaccines. Journal of feline medicine and surgery. 2024. DOI: https://doi.org/10.1177/1098612X231218643

[3] Gong Y, Chen T, Feng N, Meng X, Sun W, Wang T, et al.. A highly efficient recombinant canarypox virus-based vaccine against canine distemper virus constructed using the CRISPR/Cas9 gene editing method.. Veterinary Microbiology. 2020. DOI: https://doi.org/10.1016/j.vetmic.2020.108920

[4] Liu F, Niu Q, Fan X, Liu C, Zhang J, Wei Z, et al.. Priming and activation of inflammasome by canarypox virus vector ALVAC via the cGAS/IFI16-STING-Type I IFN pathway and AIM2 sensor. Journal of Immunology. 2017. DOI: https://doi.org/10.4049/jimmunol.1700698

[5] Anasir M, Baxter AA, Poon I, Hulett M, Kvansakul M. Structural and Functional Insight into Canarypox Virus CNP058 Mediated Regulation of Apoptosis. Viruses. 2017. DOI: https://doi.org/10.3390/v9100305

[6] Shaib H, Barbour E. Characterization of a canarypox virus from an outbreak among canaries (Serinus canaria domesticus) in Lebanon. Journal of Applied Animal Research. 2018. DOI: https://doi.org/10.1080/09712119.2018.1434079

[7] Lee D, Lee E, Seo J, Ko E. Evaluation of concurrent vaccinations with recombinant canarypox equine influenza virus and inactivated equine herpesvirus vaccines. Journal of Animal Science and Technology. 2022. DOI: https://doi.org/10.5187/jast.2022.e30

[8] El-Hage C, Hartley C, Savage C, Watson J, Gilkerson J, Paillot R. Assessment of Humoral and Long-Term Cell-Mediated Immune Responses to Recombinant Canarypox-Vectored Equine Influenza Virus Vaccination in Horses Using Conventional and Accelerated Regimens Respectively. Vaccines. 2022. DOI: https://doi.org/10.3390/vaccines10060855

[9] Patel M, Carritt K, Lane J, Jayappa H, Stahl M, Bourgeois M, et al.. Comparative Efficacy of Feline Leukemia Virus (FeLV) Inactivated Whole-Virus Vaccine and Canarypox Virus-Vectored Vaccine during Virulent FeLV Challenge and Immunosuppression. Clinical and Vaccine Immunology. 2015. DOI: https://doi.org/10.1128/CVI.00034-15

[10] Guillaume-Vasselin V, Lemaitre L, Dhondt K, Tedeschi L, Poulard A, Charreyre C, et al.. Protection from Hendra virus infection with Canarypox recombinant vaccine. npj Vaccines. 2016. DOI: https://doi.org/10.1038/npjvaccines.2016.3

[11] Mc P, Je B, Maćkowiak M. Protection of dogs against canine distemper by vaccination with a canarypox virus recombinant expressing canine distemper virus fusion and hemagglutinin glycoproteins.. American Journal of Veterinary Research. 1997. DOI: https://doi.org/10.2460/ajvr.1997.58.08.833

[12] Ryan E, Harenberg A, Burdin N. The Canarypox-virus vaccine vector ALVAC triggers the release of IFN-γ by Natural Killer (NK) cells enhancing Th1 polarization. Vaccine. 2007. DOI: https://doi.org/10.1016/j.vaccine.2006.12.048

[13] Carritt K, Davis R, Stachura K, Crumley P, Mogler M, Stahl M, et al.. A Novel, Safe, Non-Adjuvanted Alphavirus Replicon-Based Vaccine Expressing the Feline Leukemia Virus Envelope Protein Protects Against Virulent FeLV Challenge. Vaccines. 2025. DOI: https://doi.org/10.3390/vaccines13070697

[14] Lee D, Eun-Bee L, Jong-Pil S, Eun-Ju K. Adjuvant combination enhances immune response of equine influenza virus vaccine in horses.. Equine Veterinary Journal. 2025. DOI: https://doi.org/10.1111/evj.70090

[15] Minhas SK, Kumar P, Panghal R, Mehtani R, Yadav R, Kalonia S, et al.. Fowl pox virus: a minireview. Worlds Poultry Science Journal. 2023. DOI: https://doi.org/10.1080/00439339.2023.2273353

[16] Jas D, Soyer C, Fornel-Thibaud PD, Oberli F, Vernes D, Guigal P, et al.. Adjuvant immunotherapy of feline injection-site sarcomas with the recombinant canarypox virus expressing feline interleukine-2 evaluated in a controlled monocentric clinical trial when used in association with surgery and brachytherapy. Trials in Vaccinology. 2015. DOI: https://doi.org/10.1016/J.TRIVAC.2014.11.001

[17] Meng X, Yan F, Wang W, Wang S, Cong H, Li J, et al.. A single dose of an ALVAC vector-based RABV virus-like particle candidate vaccine induces a potent immune response in mice, cats and dogs. Emerging Microbes and Infections. 2024. DOI: https://doi.org/10.1080/22221751.2024.2406280

[18] Abbehusen M, Cunha J, Suarez M, Teixeira C, Almeida V, Pereira LS, et al.. Immunization of Experimental Dogs With Salivary Proteins From Lutzomyia longipalpis, Using DNA and Recombinant Canarypox Virus Induces Immune Responses Consistent With Protection Against Leishmania infantum. Frontiers in Immunology. 2018. DOI: https://doi.org/10.3389/fimmu.2018.02558

[19] Zanetti F, Grand M, Mitarotonda R, Taboga O, Calamante G. Canarypox virus expressing infectious bursal disease VP2 protein as immunogen for chickens. Brazilian Journal of Microbiology. 2014. DOI: https://doi.org/10.1590/s1517-83822014000100032

[20] Girard M, Ryst E, Barré-Sinoussi F, Nara P, Tartaglia J, Paoletti E, et al.. Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus.. Virology. 1997. DOI: https://doi.org/10.1006/VIRO.1997.8560